Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development

BackgroundAlthough mRNA vaccines have been efficient for combating a variety of tumors, their effectiveness against glioma remains unclear. There is growing evidence that immunophenotyping can reflect the comprehensive immune status and microenvironment of the tumor, which correlates closely with tr...

Full description

Bibliographic Details
Main Authors: Shuai Ma, Yixu Ba, Hang Ji, Fang Wang, Jianyang Du, Shaoshan Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.738435/full
_version_ 1819136266270146560
author Shuai Ma
Shuai Ma
Yixu Ba
Yixu Ba
Hang Ji
Hang Ji
Fang Wang
Jianyang Du
Shaoshan Hu
Shaoshan Hu
author_facet Shuai Ma
Shuai Ma
Yixu Ba
Yixu Ba
Hang Ji
Hang Ji
Fang Wang
Jianyang Du
Shaoshan Hu
Shaoshan Hu
author_sort Shuai Ma
collection DOAJ
description BackgroundAlthough mRNA vaccines have been efficient for combating a variety of tumors, their effectiveness against glioma remains unclear. There is growing evidence that immunophenotyping can reflect the comprehensive immune status and microenvironment of the tumor, which correlates closely with treatment response and vaccination potency. The purpose of this research was to screen for effective antigens in glioma that could be used for developing mRNA vaccines and to further differentiate the immune subtypes of glioma to create an selection criteria for suitable patients for vaccination.MethodsGene expression profiles and clinical data of 698 glioma samples were extracted from The Cancer Genome Atlas, and RNA_seq data of 1018 glioma samples was gathered from Chinese Glioma Genome Atlas. Gene Expression Profiling Interactive Analysis was used to determine differential expression genes and prognostic markers, cBioPortal software was used to verify gene alterations, and Tumor Immune Estimation Resource was used to investigate the relationships among genes and immune infiltrating cells. Consistency clustering was applied for consistent matrix construction and data aggregation, Gene oncology enrichment was performed for functional annotation, and a graph learning-based dimensionality reduction method was applied to describe the subtypes of immunity.ResultsFour overexpressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in glioma, including TP53, IDH1, C3, and TCF12. Besides, four immune subtypes of glioma (IS1-IS4) and 10 immune gene modules were identified consistently in the TCGA data. The immune subtypes had diverse molecular, cellular, and clinical features. IS1 and IS4 displayed an immune-activating phenotype and were associated with worse survival than the other two subtypes, while IS2 and IS3 had lower levels of tumor immune infiltration. Immunogenic cell death regulators and immune checkpoints were also diversely expressed in the four immune subtypes.ConclusionTP53, IDH1, C3, and TCF12 are effective antigens for the development of anti-glioma mRNA vaccines. We found four stable and repeatable immune subtypes of human glioma, the classification of the immune subtypes of glioma may play a crucial role in the predicting mRNA vaccine outcome.
first_indexed 2024-12-22T10:32:15Z
format Article
id doaj.art-37b862405663437e973593a8716d9694
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-12-22T10:32:15Z
publishDate 2021-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-37b862405663437e973593a8716d96942022-12-21T18:29:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-09-011210.3389/fimmu.2021.738435738435Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine DevelopmentShuai Ma0Shuai Ma1Yixu Ba2Yixu Ba3Hang Ji4Hang Ji5Fang Wang6Jianyang Du7Shaoshan Hu8Shaoshan Hu9Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, ChinaTranslational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, ChinaDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, ChinaTranslational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, ChinaDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, ChinaTranslational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, ChinaDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of Neurosurgery, Emergency Medicine Center, Zhejiang Provincial People's Hospital Affiliated to Hangzhou Medical College, Hangzhou, ChinaBackgroundAlthough mRNA vaccines have been efficient for combating a variety of tumors, their effectiveness against glioma remains unclear. There is growing evidence that immunophenotyping can reflect the comprehensive immune status and microenvironment of the tumor, which correlates closely with treatment response and vaccination potency. The purpose of this research was to screen for effective antigens in glioma that could be used for developing mRNA vaccines and to further differentiate the immune subtypes of glioma to create an selection criteria for suitable patients for vaccination.MethodsGene expression profiles and clinical data of 698 glioma samples were extracted from The Cancer Genome Atlas, and RNA_seq data of 1018 glioma samples was gathered from Chinese Glioma Genome Atlas. Gene Expression Profiling Interactive Analysis was used to determine differential expression genes and prognostic markers, cBioPortal software was used to verify gene alterations, and Tumor Immune Estimation Resource was used to investigate the relationships among genes and immune infiltrating cells. Consistency clustering was applied for consistent matrix construction and data aggregation, Gene oncology enrichment was performed for functional annotation, and a graph learning-based dimensionality reduction method was applied to describe the subtypes of immunity.ResultsFour overexpressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in glioma, including TP53, IDH1, C3, and TCF12. Besides, four immune subtypes of glioma (IS1-IS4) and 10 immune gene modules were identified consistently in the TCGA data. The immune subtypes had diverse molecular, cellular, and clinical features. IS1 and IS4 displayed an immune-activating phenotype and were associated with worse survival than the other two subtypes, while IS2 and IS3 had lower levels of tumor immune infiltration. Immunogenic cell death regulators and immune checkpoints were also diversely expressed in the four immune subtypes.ConclusionTP53, IDH1, C3, and TCF12 are effective antigens for the development of anti-glioma mRNA vaccines. We found four stable and repeatable immune subtypes of human glioma, the classification of the immune subtypes of glioma may play a crucial role in the predicting mRNA vaccine outcome.https://www.frontiersin.org/articles/10.3389/fimmu.2021.738435/fullmRNA vaccineimmune subtypegliomaimmune landscapetumor antigens
spellingShingle Shuai Ma
Shuai Ma
Yixu Ba
Yixu Ba
Hang Ji
Hang Ji
Fang Wang
Jianyang Du
Shaoshan Hu
Shaoshan Hu
Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
Frontiers in Immunology
mRNA vaccine
immune subtype
glioma
immune landscape
tumor antigens
title Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
title_full Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
title_fullStr Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
title_full_unstemmed Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
title_short Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
title_sort recognition of tumor associated antigens and immune subtypes in glioma for mrna vaccine development
topic mRNA vaccine
immune subtype
glioma
immune landscape
tumor antigens
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.738435/full
work_keys_str_mv AT shuaima recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT shuaima recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT yixuba recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT yixuba recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT hangji recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT hangji recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT fangwang recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT jianyangdu recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT shaoshanhu recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment
AT shaoshanhu recognitionoftumorassociatedantigensandimmunesubtypesingliomaformrnavaccinedevelopment